Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a, Dose-finding, Open-label Trial Followed by a Phase 1b, Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Tuberculosis Subunit Vaccine H107e/CAF®10b in Adults

NCT06050356 is registered in ClinicalTrials.gov with Statens Serum Institut as lead sponsor.

NCT NCT06050356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06050356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a, Dose-finding, Open-label Trial Followed by a Phase 1b, Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Tuberculosis Subunit Vaccine H107e/CAF®10b in Adults
Lead sponsor
Statens Serum Institut
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 14, 2024
Completion date
December 31, 2026
Enrollment
140 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy